Keeping Immunotherapy Inside the Tumor: Rice-Grain-Sized Biodegradable Implant Clears Tumors in 60% of Mice

Intratumoral injection can deliver potent immunotherapy drugs directly to a lesion, but keeping them there is difficult: the drugs may be distributed unevenly or rapidly enter the circulation and affect healthy tissues. A Houston Methodist research team therefore designed a biodegradable implant about the size of a grain of rice in an effort to confine therapeutic concentrations within the tumor and extend the duration of action.

The device is called a “biodegradable nanofibrous drug-eluting seed” (b-NDES). Researchers used electrospinning to create a shell made of polycaprolactone (PCL) and poly(lactic-co-glycolic acid) (PLGA), adding barium sulfate so the implant could be identified on imaging. It functions as a miniature drug reservoir, with drugs continuously diffusing through pores in the fibers, while the device is designed to gradually degrade in the body, eliminating the need for surgical removal.

The material ratio is key to controlling the release rate. The study showed that an optimized one-to-four formulation of PCL and PLGA reduced permeable porosity from about 19% to 2.7%. In vitro testing also showed that the hourly release of a tracer substance fell from about 163 micrograms to 31 micrograms. In other words, the research team did not simply place drugs inside the tumor; it used the material’s structure to regulate how quickly they left the reservoir.

In a 4T1 triple-negative breast cancer mouse model, the implant was loaded with a CD40 agonist antibody and a STING agonist, then combined with stereotactic radiotherapy. This combination extended the drugs’ residence time within the tumor and resulted in complete tumor regression in 60% of the animals. No systemic adverse effects were observed during the study, and drug exposure outside the tumor was also very low.

The findings suggest that localized sustained release may allow a combination of immune stimulants that might otherwise cause systemic toxicity to exert a more concentrated effect within the tumor. However, “no adverse effects were observed” applies only to this mouse experiment and cannot yet be extrapolated to human safety. The study also did not demonstrate that the therapy could maintain the same effect across tumors of different sizes or locations, or in different immune environments.

The degradation data also leave practical questions. After six months, the implants had lost an average of 46.32% of their mass, demonstrating that the material gradually breaks down, but also indicating that the time required for complete degradation and the long-term tissue response to its byproducts still need to be clarified. Before entering clinical use, the team will also need to establish a stable manufacturing process and complete more comprehensive studies of toxicology, dosing, and implantation safety.

In principle, this strategy is better suited to solid tumors that can be reached with a needle or interventional procedure. The research team identified pancreatic cancer and lung cancer as possible directions, but no corresponding efficacy data are currently available. Moving from tumor clearance in mice to treatment in humans will depend not only on whether the drugs can remain in place longer, but also on whether the implantation procedure, material degradation, and immune response can be reliably controlled.